Literature DB >> 2567497

The CD2 antigen associates with the T-cell antigen receptor CD3 antigen complex on the surface of human T lymphocytes.

M H Brown1, D A Cantrell, G Brattsand, M J Crumpton, M Gullberg.   

Abstract

T lymphocytes can be activated by various stimuli directed either against the T-cell antigen receptor-CD3 antigen complex (Ti-CD3) or the CD2 molecule; see ref. 1 for a review. Activation signals generated by antigen binding to the antigen-specific alpha/beta heterodimer (Ti) are thought to be transduced via the invariant CD3 gamma, epsilon and delta chains, and the associated zeta and eta subunits. The physiological role of the interaction of CD2 with its homologous cell-surface associated ligand LFA-3 remains to be fully elucidated. It has been suggested that CD2 regulates an antigen-independent pathway of activation or that signals delivered via CD2 are an integral part of the antigen-specific pathway. Several recent studies have indicated a requirement for the Ti-CD3 complex in CD2 signalling. Thus, mutant T-cell lines expressing CD2, but not Ti-CD3, on the cell surface cannot be activated via the CD2 molecules. Functional interaction between the Ti-CD3 complex and the CD2 antigen suggests that these T-lymphocyte cell-surface structures are physically associated. Here we use a digitonin-based solubilization procedure to explore this possibility and show that 40% of the cell-surface CD2 molecules can be specifically co-precipitated in association with the Ti-CD3 complex.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2567497     DOI: 10.1038/339551a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  32 in total

1.  Association of Src-like protein tyrosine kinases with the CD2 cell surface molecule in rat T lymphocytes and natural killer cells.

Authors:  G M Bell; J B Bolen; J B Imboden
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

2.  Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5.

Authors:  A D Beyers; L L Spruyt; A F Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

3.  CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells.

Authors:  P Moingeon; J L Lucich; D J McConkey; F Letourneur; B Malissen; J Kochan; H C Chang; H R Rodewald; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

4.  Complex formation of human T-cell leukemia virus type I p40tax transactivator with cellular polypeptides.

Authors:  K Nagata; Y Ide; T Takagi; K Ohtani; M Aoshima; H Tozawa; M Nakamura; K Sugamura
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 5.  Immunosuppressive drug therapy.

Authors:  Choli Hartono; Thangamani Muthukumar; Manikkam Suthanthiran
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

6.  Basis for defective proliferation of peripheral blood T cells to anti-CD2 antibodies in primary Sjögren's syndrome.

Authors:  R Gerli; A Bertotto; E Agea; L Lanfrancone; C Cernetti; F Spinozzi; P Rambotti
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 7.  Immunobiology and immunopharmacology of organ allograft rejection.

Authors:  M Suthanthiran; T B Strom
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

8.  A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation.

Authors:  K Yamashita; C R Parish; H S Warren; L C Harrison
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

9.  T-lymphocyte activation pathways in alcoholic liver disease.

Authors:  F Spinozzi; A Bertotto; F Rondoni; R Gerli; F Scalise; F Grignani
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

Review 10.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.